%0 Journal Article
%T Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
%A Hoeh, Benedikt
%A Chun, Felix K. H.
%A Mandel, Philipp
%J Chinese Clinical Oncology
%D 2023
%B 2023
%9 
%! Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
%K 
%X 
%U https://cco.amegroups.org/article/view/117999
%V 13
%N 1
%P 14
%@ 2304-3873